Clinical Trial Update: Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial of Runihol for non-alcoholic fatty liver disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Runihol

Snippet

Sponsor: POLYSAN Scientific & Technological Pharmaceutical Company | Conditions: Non-alcoholic Fatty Liver Disease | Phase 2 | Status: TERMINATED